Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 23 February 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Immunostaining detects dysplasia in Barrett's and IBD

Alpha-methylacyl-CoA racemase is involved in the neoplastic progression in Barrett's and IBD, and may be useful to detect dysplasia in the epithelia, reports this month's American Journal of Surgical Pathology.

News image

fiogf49gjkf04

Alpha-Methylacyl-CoA racemase catalyzes the racemization of alpha-methyl, branched carboxylic coenzyme A thioesters.

It is overexpressed in a variety of neoplasms, such as prostate and colon cancer.

Dr Russell Dorer and colleagues evaluated alpha-methylacyl-CoA racemase expression in the metaplasia-dysplasia-carcinoma sequence in Barrett's, ulcerative colitis, and Crohn's.

The researchers determined whether its expression can be used to detect dysplastic epithelium in these conditions.

The research team immunostained 134 routinely processed biopsy and/or resection specimens from 134 patients with Barretts.

Immunostainings in 14 specimens were indefinite for dysplasia, 16 were low-grade dysplasia, and 32 were high-grade dysplasia.

The team also immunostained 36 invasive adenocarcinoma, and 74 specimens from 74 patients with inflammatory bowel disease (IBD).

Alpha-methylacyl-CoA racemase was expressed in 81% with high-grade dysplasia
American Journal of Surgical Pathology

The researchers immunostained the specimens with a monoclonal alpha-methylacyl-CoA racemase antibody.

The degree of cytoplasmic staining in all cases was evaluated in a blinded fashion according to a grading system.

In patients with Barrett's, alpha-methylacyl-CoA racemase was not expressed in any negative foci but was increased in foci of low-grade dysplasia by 38%.

The team found that alpha-methylacyl-CoA racemase was expressed in 81% with high-grade dysplasia, and 72% in invasive adenocarcinoma.

The researchers noted that 23% of indefinite for dysplasia foci from 3 Barrett's Esophagus patients were only focally positive.

However, 1 of these 3 patients had follow-up information available, and had developed invasive adenocarcinoma subsequently.

Similarly, in patients with IBD, the team noted that alpha-methylacyl-CoA racemase was not expressed in any foci considered negative for dysplasia.

It was significantly increased in 96% of foci with low-grade dysplasia, 80% with high-grade dysplasia, and 71% with invasive adenocarcinoma.

Only 14% of indefinite for dysplasia focus from 1 patient was focally positive.

The sensitivity for the detection of low-grade dysplasia and high-grade dysplasia in Barrett's and IBD was 38% and 81%, and 96% and 80%, respectively.

The researchers observed that the specificity was 100% for both Barrett's Esophagus and IBD.

Dr Dorer's team concludes, “Alpha-methylacyl-CoA racemase is involved in the neoplastic progression in Barrett's Esophagus and IBD.”

“The high degree of specificity of alpha-methylacyl-CoA racemase for dysplasia/carcinoma in Barrett's Esophagus and IBD suggests that it may be useful to detect neoplastic epithelium in these conditions.”

Am J Surg Path 2006: 30(7): 871-7
12 July 2006

Go to top of page Email this page Email this page to a colleague

 23 February 2018 
MRI and NAFLD
 23 February 2018 
Heavy metals on a gluten-free diet
 23 February 2018 
Patients on antithrombotic agents undergoing emergency and elective endoscopy
 22 February 2018 
Autophagy enhancers
 22 February 2018 
Outcomes with Crohn’s after infliximab withdrawal
 22 February 2018 
Elderly onset of IBD

 21 February 2018 
Adalimumab and infliximab in biologic-naïve Crohn's
 21 February 2018 
Cystic fibrosis and colorectal cancer
 21 February 2018 
Management of hemorrhoids in the USA
 20 February 2018 
Treatment algorithm for polyp cancers
 20 February 2018 
Predictors of postoperative infection in Crohn's
 20 February 2018 
Complications and surveillance colonoscopies
 19 February 2018 
Screening colonoscopy in the right and left colon
 19 February 2018 
NAFLD prevalence in the USA
 19 February 2018 
Fructans in children with IBS

 16 February 2018 
Undetected celiac in the elderly
 16 February 2018 
Inflammatory bowel diseases are global diseases
 16 February 2018 
Fructans induce non-celiac gluten sensitivity
 15 February 2018 
NSAIDS and GI damage
 15 February 2018 
Oral direct-acting antiviral treatment for Hep C virus genotype 1
 15 February 2018 
Primary vs secondary surgery for the presence of lymph node metastasis
 14 February 2018 
Predicting adenoma detection rate
 14 February 2018 
Normal bowel frequency characterization in the USA 
 13 February 2018 
Personalising treatment options for IBS
 13 February 2018 
Prebiotics improve endothelial dysfunction
 13 February 2018 
Diagnostic criteria for a Rome IV functional gastrointestinal disorders
 12 February 2018 
Visceral hypersensitivity and functional GI disorders
 12 February 2018 
Depression and aggressive IBD
 12 February 2018 
Variability in interpretation of endoscopic findings impacts patient management
 09 February 2018 
Treatment of choice for anastomotic stricture in IBD
 09 February 2018 
PRO measurement information system 
 09 February 2018 
Overall disease severity indices for IBD
 08 February 2018 
Prediction of endoscopically active disease

 08 February 2018 
Steroid-refractory acute severe ulcerative colitis
 08 February 2018 
Decision aid used by IBD patients
 07 February 2018 
Ursodeoxycholic acid combined with bezafibrate for itching
 07 February 2018 
Change in microbiome in gastritis vs gastric carcinoma
 07 February 2018 
Colorectal cancer and primary sclerosing cholangitis-IBD
 06 February 2018 
Risk of death after liver transplantation
 06 February 2018 
Crohn’s disease vs refractory pouchitis
 06 February 2018 
Support for functional dyspepsia symptom diary
 05 February 2018 
Helicobacter spp influence on GI tract 
 05 February 2018 
No link found between severe reflux and all-cause mortality 
 05 February 2018 
Psychological distress in PPI non-responders
 02 February 2018 
Assessing psychosexual impact of IBD
 02 February 2018 
Decrease in overall mortality with cholera vaccination
 02 February 2018 
Diagnostic performance of fecal immunochemical tests
 01 February 2018 
Screening frequency with family histories of colorectal cancer
 01 February 2018 
IBD and sport participation
 01 February 2018 
Life with a stoma 
 31 January 2018 
Aprepitant and gastroparesis 
 31 January 2018 
Anesthesia risk in colonoscopy
 31 January 2018 
GED-0301 for Crohn's Disease
 30 January 2018 
Intestinal dysbiosis and allergic diseases in infants
 30 January 2018 
Fructans and IBS symptoms in children
 29 January 2018 
Dosing calculator for therapy optimization in IBD
 29 January 2018 
Glecaprevir–pibrentasvir for in HCV
 29 January 2018 
Food allergen injections in eosinophilic esophagitis
 29 January 2018 
Reliability of the IBD index
 26 January 2018 
Tofacitinib vs biological therapies for ulcerative colitis

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us